Proton Therapy
Proton Therapy Australia is a Sydney-based, pre-operational healthcare company developing Australia's first private proton therapy cancer treatment centre, using IBA-supplied proton beam technology, targeting first patient treatment by 2029 pending closing of seed funding via Thames Capital.
- Company typePrivate
- Founded2006
- HeadquartersSydney, Australia
- Headcount11–50
- GTM typeB2C
- OfferingServices
What Proton Therapy does
Proton Therapy Australia Pty Ltd is a Sydney-based, pre-operational healthcare company developing what it intends to be Australia's first private proton therapy cancer treatment centre. The company plans to operate a single-room clinic at 100 Botany Road, Waterloo, using proton beam radiation therapy — an advanced form of external beam radiotherapy that exploits the Bragg peak principle to deliver most of a proton beam's energy at a precise depth within the tumour while minimising exit dose to surrounding healthy tissue. Technology will be supplied under partnership with IBA (Belgium), the global market leader in proton therapy systems, with reference to its ConformalFLASH capability.
The intended operating model follows an Australian private hospital structure with open access to proton-accredited radiation oncologists from both the public and private sectors. Revenue is expected to derive from per-patient treatment fees supplemented by Medicare rebates for eligible indications — with the company citing a government estimate that 2,342 Australians annually could qualify for Medicare reimbursement by 2025 under existing and potential future clinical indications, against a broader addressable market of 8,000+ Australians per year. The company is also building national and international referral networks through a yet-to-be-announced clinical partner and a knowledge-sharing relationship with the University of Florida Health Proton Therapy Institute.
The company is currently in the fundraising stage, having appointed Thames Capital to raise the final tranche of seed capital required to reach first patient treatment, targeted for 2029. Leadership comprises Managing Director Susanne Bleasel (who originally developed the business case for Australian proton therapy) and Chair Dr John O'Donnell AM (experienced across Australian public, private and charitable healthcare sectors). The single-room clinic design is explicitly intended to be replicable to additional sites, signalling a national multi-centre strategy once the flagship is operational.
Proton Therapy firmographics
Firmographics- Name
- Proton Therapy
- Legal name
- Proton Therapy Australia Pty Ltd
- Website
- https://protontherapy.com.au
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Proton Therapy Australia is a Sydney-based, pre-operational healthcare company developing Australia's first private proton therapy cancer treatment centre, using IBA-supplied proton beam technology, targeting first patient treatment by 2029 pending closing of seed funding via Thames Capital.
- Ownership category
- akta.pro rank
Proton Therapy industry classification
Industry- Product category
- Radiation Oncology Services
- NAICS
- Diagnostic Imaging Centers (621512)
- SIC
- Services-Specialty Outpatient Facilities, Nec (8093)
- akta.pro primary industry
- Radiation Oncology (HLAKAFAC)
- akta.pro secondary industries
- Nuclear Medicine Clinical Services & Therapy Centers (HLAIAGAI), Radiation Therapy Planning & Simulation Imaging (CT Sim/MR Sim) (HLAHABAH)
Keywords
Where Proton Therapy is headquartered
LocationHeadquarters
- HQ city
- Sydney
- HQ country
- Australia
- HQ region
- Oceania
Offices2 records
Markets served
Proton Therapy business model
Business model- GTM type
- B2C
- Offering type
- Services
- Cost components
- Infrastructure, Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Proton Therapy Treatment Services: The company will operate as a private hospital/clinic model providing proton therapy treatment services to cancer patients. Revenue will come from patient treatment fees and Medicare rebates for eligible patients. Government estimates 2,342 Australians annually could qualify for proton therapy reimbursement under existing and potential future Medicare indications by 2025.
- Medicare Rebates: Government funding through Medicare rebates for proton therapy treatment for eligible cancer patients, based on clinical indications.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Treatment services - pricing not publicly disclosed |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels5 records
Proton Therapy product offering
Product offeringCore offering
Proton Therapy Australia is developing a private proton beam therapy clinic in Sydney to treat cancer patients using IBA (Belgium) technology, leveraging the Bragg Peak phenomenon to deliver targeted radiation to tumors while sparing surrounding healthy tissue. The phased rollout begins with a Single Room Clinic (target first patient treatment 2029), expanding to a 4-room facility and ultimately a 10-room National Centre. The service targets Australian patients across pediatric, brain, head and neck, prostate, breast, and lung cancer indications.
Product overview
Proton Therapy Australia is a single-location healthcare facility offering proton therapy cancer treatment services. The company is developing the first private proton therapy clinic in Australia, featuring a single-room design capable of easy replication to other locations. The service provides advanced radiation therapy using positively charged proton particles that can be precisely targeted at tumours while minimizing damage to surrounding healthy tissue. The operating model follows an Australian private hospital structure with open access to proton-accredited radiation oncologists from both public and private sectors. The facility has partnered with IBA (Belgium) as its technology provider and expects to begin treating patients by 2029.
Differentiator
Problem solved
Functional benefit
Products and services
- Single Room Proton Therapy Clinic Standalone single-room proton beam therapy clinic planned for Sydney, providing targeted radiation treatment for Australian cancer patients using IBA (Belgium) technology; serves patients with pediatric, brain, head and neck, prostate, breast, and lung cancers, and is the first phase of a staged national rollout.
Quantifiable outcome
- 8,000+ Australians could benefit annually from proton therapy
- +2 more outcomes
Companies that use Proton Therapy
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
Proton Therapy technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature1 record
Proton Therapy partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- IBA (Belgium)coreWorld-leading technology partner for proton therapy. IBA is a world leader in proton therapy technology. Proton Therapy Australia will use IBA's proton therapy technology and equipment at their Sydney facility. Reference to IBA's ConformalFLASH technology mentioned.
- University of Florida, USA Health Proton Therapy InstitutecoreDr Daniel Indelicato from the University of Florida Proton Therapy Institute visited Australia in June 2024 to speak at the Paediatric Radiation Oncology Society Meeting in Sydney. Dr Indelicato has treated Australian children who travelled to Florida for proton therapy. Sharing expertise on what Australia should know about setting up proton therapy.
- Clinical Partner (Name to be announced)coreProton Therapy Australia is finalising arrangements with a leading clinical partner to support delivery of world-class proton therapy services. The appointment will be announced following completion of operating agreements. Expected to provide national and international referral networks, exceptional patient care, multidisciplinary workforce, clinical research, education and training.
- World-Class Clinicians and ResearcherscorePartnership with world-class clinicians, researchers, and technology providers as part of mission to bring world-class proton therapy to Australia. Includes Dr John O'Donnell AM as Chair with national experience across public, private and charitable healthcare sectors.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
Proton Therapy competitors and assessment
Company assessmentDirect peers
- IBA (Ion Beam Applications): Belgium-based world leader in proton therapy technology and equipment. PTA is both a customer and direct sector peer, as IBA's commercial success depends on building proton therapy centres globally—including PTA's planned Sydney facility using IBA's ConformalFLASH technology.
- Provision Healthcare: US operator of proton therapy centres (Provision CARES) and developer of proton therapy projects. Directly comparable as a private-sector developer and operator of proton therapy clinics targeting similar clinical use cases.
- Mevion Medical Systems: US-based proton therapy system manufacturer focused on compact, single-room proton therapy systems. Highly comparable to PTA's single-room clinic model and a direct competitor to IBA in supplying proton therapy technology.
- Proton International: US-based company that develops, equips, and operates proton therapy centres for hospitals and health systems. Directly comparable in business model as a proton therapy centre developer pursuing first-mover opportunities in untapped markets.
Regional players
- Sydney Adventist Hospital (San Radiation Oncology): Australian private hospital operator running a radiation oncology service in Sydney. Comparable as a regional incumbent that could become a partner, competitor, or referrer to PTA's planned Waterloo facility.
- GenesisCare: Australia-headquartered private cancer care provider with a national radiation oncology network. Comparable as a regional operator that could partner with, compete with, or supply referral patients to PTA's planned centre.
Others
- Hitachi (former proton therapy business): Originally one of the three global proton therapy system manufacturers alongside IBA and Varian. Susanne Bleasel developed PTA's business case for Hitachi before founding Proton Therapy Australia, making Hitachi a relevant historical and ecosystem peer.
Broad incumbents
- Varian Medical Systems (Siemens Healthineers): Global leader in radiation oncology hardware and software, now part of Siemens Healthineers. Provides conventional and advanced photon radiation therapy systems that compete with proton therapy for the same oncology indications.
- Elekta: Swedish-based incumbent in radiation therapy and radiosurgery equipment, including linear accelerators used in conventional radiotherapy. Competes indirectly with proton therapy for hospital capital budgets and oncology treatment referrals.
Emerging players
- ProNova Solutions: US-based developer of compact, single-room proton therapy systems. Comparable to PTA as another emerging player pursuing smaller-footprint, lower-cost proton therapy delivery models.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
Proton Therapy social profiles
Digital presenceProton Therapy financial estimates
Financial estimateRevenue estimate
Valuation estimate
Proton Therapy leadership team
Management profileNumber of profiles
Profiles2 records
Proton Therapy funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Proton Therapy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Proton Therapy
What does Proton Therapy do?
Proton Therapy Australia is developing a private proton beam therapy clinic in Sydney to treat cancer patients using IBA (Belgium) technology, leveraging the Bragg Peak phenomenon to deliver targeted radiation to tumors while sparing surrounding healthy tissue. The phased rollout begins with a Single Room Clinic (target first patient treatment 2029), expanding to a 4-room facility and ultimately a 10-room National Centre. The service targets Australian patients across pediatric, brain, head and neck, prostate, breast, and lung cancer indications.
Is Proton Therapy a public or private company?
Proton Therapy is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Proton Therapy founded?
Proton Therapy was founded in 2006. It employs 11 to 50 people.
Where is Proton Therapy based?
Proton Therapy is headquartered in Sydney, Australia, in the Oceania region.
How does Proton Therapy make money?
Two revenue lines are on record. Proton Therapy Treatment Services are the primary driver. The others are medicare Rebates.
Who are Proton Therapy's main competitors?
Direct peers on record are IBA (Ion Beam Applications), Provision Healthcare, Mevion Medical Systems and Proton International. Regional players are Sydney Adventist Hospital (San Radiation Oncology) and GenesisCare. Hitachi (former proton therapy business) is listed as an others. Broad incumbents are Varian Medical Systems (Siemens Healthineers) and Elekta. ProNova Solutions is listed as an emerging player.
Does Proton Therapy have an API?
No public API is recorded for Proton Therapy.
What industry is Proton Therapy in?
Proton Therapy's product category is Radiation Oncology Services. Its primary akta.pro industry code is HLAKAFAC, Radiation Oncology, with a secondary code of HLAIAGAI, Nuclear Medicine Clinical Services & Therapy Centers. Its NAICS code is 621512 and its SIC code is 8093.